Esbriet And Ofev Reviewers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA staff who participated in the review of InterMune’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for treatment of idiopathic pulmonary fibrosis.